Skip to main content
Medical information Clinical review pending

Genetic Testing

Spastic Paraplegia Panel Genetic Test

The Spastic Paraplegia Panel NGS Genetic DNA Test uses advanced sequencing technology to identify genetic mutations associated with spastic paraplegia, a neurological disorder causing progressive leg weakness and stiffness. This test helps in diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample (typically 5-10ml) collected in an EDTA tube. Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Patients can eat and drink normally before the sample collection.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Spastic Paraplegia Panel Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals experiencing symptoms of progressive leg weakness and stiffness.
  • ✓Patients with a family history of spastic paraplegia or related neurological disorders.
  • ✓Individuals seeking genetic confirmation for a clinical diagnosis.
  • ✓Patients considering family planning with a known family history of the condition.
02

In plain language

What this test helps you understand

This test helps identify the specific genetic cause of spastic paraplegia, aiding in diagnosis, prognosis, and guiding management strategies. It can also inform genetic counseling for affected families.
The Spastic Paraplegia Panel NGS Genetic DNA Test is an advanced diagnostic tool that utilizes Next Generation Sequencing (NGS) technology to identify genetic mutations linked to spastic paraplegia. This neurological disorder is characterized by progressive weakness and stiffness of the legs, significantly impacting mobility and quality of life. Understanding the genetic underpinnings of this condition is essential for effective management and treatment.

This test detects specific genetic mutations that may cause or contribute to spastic paraplegia. By analyzing the DNA from blood or extracted samples, healthcare providers can gain insights into the hereditary nature of the disorder, enabling them to tailor treatment plans for affected individuals.

Taking the Spastic Paraplegia Panel NGS Genetic DNA Test offers numerous benefits, including accurate identification of genetic mutations, informed decision-making regarding treatment and management, guidance for family planning and risk assessment for relatives, and access to targeted therapies and support resources.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Patients can eat and drink normally before the sample collection.
SampleA blood sample (typically 5-10ml) collected in an EDTA tube. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze DNA extracted from the patient's blood sample, targeting genes known to be associated with spastic paraplegia.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test may not detect all possible genetic mutations associated with spastic paraplegia. Results should be interpreted in conjunction with clinical findings and family history. Variants of uncertain significance may be identified.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Spastic paraplegia is a group of inherited neurological disorders characterized by progressive stiffness (spasticity) and weakness in the legs.
Genetic testing can identify the specific gene mutation causing the condition, which helps confirm the diagnosis, understand the inheritance pattern, and guide management.
This test is recommended for individuals with symptoms of spastic paraplegia or those with a family history of the condition.
A blood sample is required for this test. Confirm specific requirements with the laboratory before booking.
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
While the test identifies the genetic cause, treatment decisions are made by your doctor based on the results, your specific symptoms, and other clinical factors.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp